Tag: Antiviral Drugs Market Statistics

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Antivirals Market Value Growth And Long-Term Outlook

The antivirals market has experienced significant growth in recent years. Its value is anticipated to rise from $114.4 billion in 2025 to $122.08 billion in 2026, representing a compound annual growth rate (CAGR) of 6.7%. This historical expansion can be attributed to factors such as global viral outbreaks, the prevalence of HIV and hepatitis, government initiatives for antiviral stockpiling, the increased availability of generic medications, and the broadening scope of infectious disease programs.

The antivirals market is projected to experience substantial expansion over the coming years. This market is set to reach $163.33 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.5%. Factors driving this growth during the forecast period include the emergence of new viral threats, increased investment in antiviral research and development, greater integration of vaccination and treatment strategies, various global health initiatives, and a rising demand for rapid-response therapeutics. Key trends anticipated in this period encompass an escalating demand for broad-spectrum antivirals, a heightened emphasis on pandemic preparedness, the wider availability of generic antiviral drugs, increased application in managing chronic viral infections, and the innovation of antivirals with novel mechanisms.

Get A Free Sample Report With In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2437&type=smp&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Antivirals Market Development Factors: What’s Supporting Demand?

A projected increase in influenza cases is expected to stimulate the expansion of the antiviral market moving forward. Influenza, commonly known as flu, is a highly transmissible viral respiratory infection caused by influenza viruses, affecting the nose, throat, and lungs. The rising frequency of influenza is largely due to colder temperatures and indoor crowding, conditions that prolong the virus’s survival and facilitate its person-to-person spread in close proximity. Antivirals are utilized for treating influenza and function by hindering the replication and propagation of influenza viruses within the body. For instance, in November 2024, as reported by the Centers for Disease Control and Prevention, a US-based national public health agency, the 2023 to 2024 influenza season was estimated to have resulted in 40 million illnesses, 18 million medical visits, 470,000 hospitalizations, and 28,000 deaths. Consequently, the escalating incidence of influenza is propelling the growth of the antiviral market.

Antivirals Market Segment Trends And Revenue Contributors

The antivirals market covered in this report is segmented –

1) By Type: Branded, Generic

2) By Drug Class: DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Other Drug classes

3) By Application: HIV, Hepatitis, Herpes, Influenza, Other Applications

Subsegments:

1) By Branded: Antivirals For HIV Or AIDS, Antivirals For Hepatitis, Antivirals For Influenza, Antivirals For Herpes Simplex Virus (HSV)

2) By Generic: Generic HIV Or AIDS Antivirals, Generic Hepatitis Antivirals, Generic Influenza Antivirals, Generic Herpes Simplex Virus (HSV) Antivirals

Antivirals Market Transformation Trends: What Innovations Are Driving Change?

Major companies in the antiviral market are prioritizing the development of innovative treatments, such as oral antiviral medications, to enhance patient adherence, improve accessibility, reduce healthcare expenses, and offer more convenient and effective options for managing viral infections. Oral antiviral treatment refers to medicines taken by mouth to combat viral infections. These treatments function by inhibiting viruses from multiplying or spreading within the body, which helps to lessen the severity and duration of the infection. For instance, in May 2023, Pfizer, a US-based pharmaceutical company, announced that Paxlovid received approval from the Food and Drug Administration, a US-based government agency, making it the first oral antiviral treatment for COVID-19 in adults. This approval is particularly significant as it offers a new therapeutic alternative for managing COVID-19, especially as the pandemic moves towards an endemic phase. Paxlovid is specifically indicated for adults with mild-to-moderate COVID-19 who are at high risk of progressing to severe disease, including hospitalization or death.

Leading companies in the antiviral market are focused on creating advanced therapeutic solutions, including various antiviral treatments, to improve patient outcomes and decrease viral transmission. Antiviral treatments are crucial for controlling viral infections and preventing complications in affected patients. For example, in August 2024, Red Queen’s Technology, a US-based pharmaceutical company, launched versatile antivirals. Apple Tree Partners has invested $55 million in Red Queen Therapeutics, a biotech firm specializing in developing broad-spectrum antiviral treatments. The company targets infectious pathogens such as COVID-19 and influenza, having already advanced a COVID antiviral through Phase 1 testing and secured U.S. government funding for a pan-influenza drug. Co-founded by Harvard professor Loren Walensky, Red Queen utilizes stapled lipopeptides to inhibit viral fusion and block viral entry into cells.

Antivirals Market Competitive Landscape: Which Companies Lead The Industry?

Major companies operating in the antivirals market are AbbVie Inc., Bristol-Myers-Squibb Co., Chemical Industrial & Pharmaceutical Laboratories Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson & Johnson Services Ltd., Merck & Co. Inc., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Abbott Laboratories, Schering-Plough Corporation, Pfizer Inc., Sanofi-Synthélabo Ltd., Inovio Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., AVI Biopharma International Ltd., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Biogen Inc., Genentech USA Inc., Vertex Pharmaceuticals Inc.

View The Full Antivirals Market Report:

https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Antivirals Market Regional Analysis And Leading Geography

North America was the largest region in the anti-viral drug therapy market in 2025. The Middle East is expected to be the fastest-growing region in the antivirals market during the forecast period. The regions covered in the antivirals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Antivirals Market Growth Analysis: How Will Revenue Expand During The Forecast Period?

The market for antivirals has experienced robust expansion in recent years, with projections indicating an increase from $114.4 billion in 2025 to $122.08 billion in 2026, representing a compound annual growth rate (CAGR) of 6.7%. This historical growth has been driven by factors such as worldwide viral epidemics, the high prevalence of HIV and hepatitis, government initiatives involving antiviral stockpiling, the widespread availability of generic medications, and the extension of infectious disease management programs.

Projections indicate that the antivirals market will continue its robust expansion in the coming years, reaching $163.33 billion by 2030 with a compound annual growth rate of 7.5%. Key drivers behind this forecasted growth include the emergence of new viral threats, heightened investment in antiviral research and development, greater alignment between vaccination programs and treatment strategies, global health initiatives, and a pressing need for therapeutics that can be deployed rapidly. Notable trends shaping the market involve a growing preference for broad-spectrum antivirals, an intensified emphasis on pandemic readiness, a wider availability of generic antiviral medications, expanded application in managing chronic viral infections, and the advancement of antivirals operating through novel mechanisms.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2437&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Antivirals Market Growth Drivers And Industry Catalysts

The growing number of influenza cases is expected to drive expansion in the antiviral market moving forward. Influenza, commonly referred to as the flu, is a highly contagious viral respiratory illness caused by influenza viruses that impact the nose, throat, and lungs. This rise in flu prevalence is largely attributed to colder temperatures and indoor gatherings, which enable the virus to persist longer and increase transmission among people in close quarters. Antivirals are employed to treat influenza by preventing the replication and spread of these viruses throughout the body. As an example, in November 2024, the Centers for Disease Control and Prevention, a US-based national public health agency, reported that the 2023 to 2024 flu season was linked to an estimated 40 million illnesses, 18 million medical visits, 470,000 hospitalizations, and 28,000 deaths. Consequently, the escalating incidence of influenza is fueling the growth of the antiviral market.

Antivirals Market Segmentation: How Is The Market Structured Across Key Categories?

The antivirals market covered in this report is segmented –

1) By Type: Branded, Generic

2) By Drug Class: DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Other Drug classes

3) By Application: HIV, Hepatitis, Herpes, Influenza, Other Applications

Subsegments:

1) By Branded: Antivirals For HIV Or AIDS, Antivirals For Hepatitis, Antivirals For Influenza, Antivirals For Herpes Simplex Virus (HSV)

2) By Generic: Generic HIV Or AIDS Antivirals, Generic Hepatitis Antivirals, Generic Influenza Antivirals, Generic Herpes Simplex Virus (HSV) Antivirals

Antivirals Market Trends Influencing Long-Term Demand

Leading players within the antiviral market are concentrating their efforts on creating cutting-edge therapies like oral antiviral medications aimed at boosting patient adherence, improving accessibility, lowering healthcare expenses, and delivering more convenient and effective solutions for managing viral diseases. An oral antiviral treatment is a medication taken by mouth that targets viral infections. These drugs function by preventing viruses from replicating or disseminating throughout the body, thereby lessening infection severity and duration. For example, in May 2023, Pfizer—a pharmaceutical company headquartered in the US—secured approval for Paxlovid, designating it as the first oral antiviral for COVID-19 in adults from the Food and Drug Administration, a US government entity. This endorsement holds particular importance as it introduces a fresh therapeutic choice for controlling COVID-19, especially as the pandemic shifts toward an endemic stage. Paxlovid is specifically intended for adults experiencing mild-to-moderate COVID-19 who face a heightened risk of advancing to severe illness, including hospitalization or death.

Key businesses active in the antiviral sector are emphasizing the development of sophisticated therapeutic approaches, like antiviral treatments, to improve patient results and curb viral spread. Antiviral therapies play a critical role in managing viral infections and averting complications in afflicted individuals. As an illustration, in August 2024, Red Queen’s Technology, a US-based pharmaceutical firm, introduced versatile antivirals. Apple Tree Partners committed $55 million to Red Queen Therapeutics, a biotech enterprise creating broad-spectrum antiviral solutions. The company addresses infectious agents such as COVID-19 and influenza, having already advanced a COVID antiviral through Phase 1 clinical trials and obtained US government support for a pan-influenza medication. Co-founded by Harvard professor Loren Walensky, Red Queen utilizes stapled lipopeptides to impede viral fusion and block viral entry into host cells.

Antivirals Market Competitive Landscape And Leading Companies

Major companies operating in the antivirals market are AbbVie Inc., Bristol-Myers-Squibb Co., Chemical Industrial & Pharmaceutical Laboratories Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson & Johnson Services Ltd., Merck & Co. Inc., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Abbott Laboratories, Schering-Plough Corporation, Pfizer Inc., Sanofi-Synthélabo Ltd., Inovio Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., AVI Biopharma International Ltd., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Biogen Inc., Genentech USA Inc., Vertex Pharmaceuticals Inc.

Access The Complete Antivirals Market Report:

https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Antivirals Market Regional Distribution: Which Areas Drive Market Expansion?

North America was the largest region in the anti-viral drug therapy market in 2025. The Middle East is expected to be the fastest-growing region in the antivirals market during the forecast period. The regions covered in the antivirals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

From Its 2026 Market Size, What Value Is The Antivirals Market Projected To Reach By 2030?

The antivirals market has experienced significant growth in recent years. This market is anticipated to expand from $114.4 billion in 2025 to $122.08 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.7%. Several factors have contributed to its historical growth, including widespread global viral outbreaks, the persistent burden of HIV and hepatitis, government initiatives for antiviral stockpiling, the increasing availability of generic medications, and the expansion of infectious disease programs.

The antivirals market is anticipated to show substantial growth in the upcoming years. It is projected to expand to $163.33 billion by 2030, achieving a compound annual growth rate (CAGR) of 7.5%. This growth during the forecast period is attributed to factors such as emerging viral threats, increased investment in antiviral research and development, enhanced vaccination and treatment integration, global health initiatives, and a demand for rapid-response therapeutics. Significant trends in the forecast period include a rising demand for broad-spectrum antivirals, a growing emphasis on pandemic preparedness, the expansion of generic antiviral drugs, increased usage in chronic viral infections, and the development of novel mechanism antivirals.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2437&type=smp

What Factors Are Contributing To The Growth Of The Antivirals Market?

A growing occurrence of influenza is expected to stimulate the expansion of the antiviral market moving ahead. Influenza, commonly known as the flu, is a highly transmissible viral respiratory infection caused by influenza viruses, impacting the nose, throat, and lungs. The increasing spread of influenza is largely attributable to colder conditions and indoor congregations, factors that extend the virus’s survival and promote close-contact transmission between individuals. Antivirals serve in treating influenza, functioning to hinder the reproduction and dissemination of influenza viruses inside the body. As an illustration, in November 2024, the Centers for Disease Control and Prevention, a national public health agency based in the US, reported that the 2023 to 2024 influenza season was estimated to have resulted in 40 million illnesses, 18 million medical visits, 470,000 hospitalizations, and 28,000 deaths. Consequently, the heightened frequency of influenza cases is boosting the expansion of the antiviral market.

How Is Segmentation Applied In The Antivirals Market Segment Analysis?

The antivirals market covered in this report is segmented –

1) By Type: Branded, Generic

2) By Drug Class: DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Other Drug classes

3) By Application: HIV, Hepatitis, Herpes, Influenza, Other Applications

Subsegments:

1) By Branded: Antivirals For HIV Or AIDS, Antivirals For Hepatitis, Antivirals For Influenza, Antivirals For Herpes Simplex Virus (HSV)

2) By Generic: Generic HIV Or AIDS Antivirals, Generic Hepatitis Antivirals, Generic Influenza Antivirals, Generic Herpes Simplex Virus (HSV) Antivirals

What Market Trends Are Affecting The Antivirals Market?

Leading companies in the antiviral market are concentrating on developing groundbreaking treatments, like oral antiviral options, to enhance patient adherence, increase availability, lower healthcare expenditures, and provide more convenient and effective methods for managing viral illnesses. Oral antiviral treatments are medicines taken orally to combat viral infections. These therapies function by hindering viruses from replicating or spreading within the body, which helps to diminish the infection’s severity and duration. For instance, in May 2023, US-based pharmaceutical company Pfizer announced that Paxlovid received approval from the US government agency, the Food and Drug Administration, as the first oral antiviral treatment for COVID-19 in adults. This approval holds particular importance as it introduces a new therapeutic avenue for managing COVID-19, especially as the pandemic moves towards an endemic phase. Paxlovid is specifically prescribed for adults with mild-to-moderate COVID-19 who are at elevated risk for advancing to severe disease, including needing hospitalization or facing death.

Prominent companies within the antiviral market are dedicated to developing advanced therapeutic solutions, such as new antiviral treatments, to improve patient results and lessen viral transmission. Antiviral treatments are crucial for managing viral infections and preventing severe complications in patients. For example, in August 2024, Red Queen’s Technology, a US-based pharmaceutical company, introduced versatile antivirals. Apple Tree Partners has invested $55 million in Red Queen Therapeutics, a biotech firm specializing in developing broad-spectrum antiviral treatments. The company focuses on infectious pathogens such as COVID-19 and influenza, having successfully moved a COVID antiviral through Phase 1 testing and secured U.S. government funding for a pan-influenza drug. Co-founded by Harvard professor Loren Walensky, Red Queen uses stapled lipopeptides to inhibit viral fusion and block the entry of viruses into cells.

Who Are The Companies Participating In The Antivirals Market Environment?

Major companies operating in the antivirals market are AbbVie Inc., Bristol-Myers-Squibb Co., Chemical Industrial & Pharmaceutical Laboratories Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson & Johnson Services Ltd., Merck & Co. Inc., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Abbott Laboratories, Schering-Plough Corporation, Pfizer Inc., Sanofi-Synthélabo Ltd., Inovio Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., AVI Biopharma International Ltd., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Biogen Inc., Genentech USA Inc., Vertex Pharmaceuticals Inc.

Get The Full Antivirals Market Report:

https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report

Which Region Leads The Antivirals Market In Terms Of Market Share?

North America was the largest region in the anti-viral drug therapy market in 2025. The Middle East is expected to be the fastest-growing region in the antivirals market during the forecast period. The regions covered in the antivirals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Antivirals Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report

Browse Through More Reports Similar to the Global Antivirals Market 2026, By The Business Research Company

Antivirals Market Report 2026

https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report

Antiviral Combination Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/antiviral-combination-therapy-global-market-report

Anti Infective Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Will Be The Estimated Market Valuation Of The Antivirals Market By The End Of 2030?

The antivirals market size has seen substantial growth in recent years. It is forecast to increase from $114.4 billion in 2025 to $122.08 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.7%. Historically, this expansion is attributable to global viral outbreaks, the burden of HIV and hepatitis, government initiatives for antiviral stockpiling, the widespread availability of generics, and the broadening of infectious disease programs.

The antivirals market is projected to experience substantial expansion in the coming years. This market is set to reach a value of $163.33 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.5%. This anticipated growth during the forecast period is primarily driven by factors such as new viral threats, increased investment in antiviral research and development, better integration of vaccination and treatment strategies, various global health initiatives, and the rising need for rapid-response therapeutic solutions. Key trends anticipated in the same period involve a heightened demand for broad-spectrum antiviral agents, an increasing emphasis on preparing for pandemics, the proliferation of generic antiviral medications, greater application in the management of chronic viral infections, and the innovation of antivirals with new mechanisms of action.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2437&type=smp

What Drivers Are Shaping The Future Growth Of The Antivirals Market?

The escalating occurrence of influenza is predicted to boost the expansion of the antiviral market moving forward. Influenza, commonly referred to as flu, is a highly transmissible viral respiratory infection, caused by influenza viruses that impact the nose, throat, and lungs. The rising prevalence of influenza stems primarily from colder conditions and indoor crowding, factors that prolong the virus’s survival and facilitate person-to-person transmission in close quarters. Antivirals are utilized for treating influenza, designed to impede the replication and dissemination of influenza viruses within the body. As an illustration, in November 2024, information from the Centers for Disease Control and Prevention, a US-based national public health agency, showed that the 2023 to 2024 influenza season was estimated to be linked to 40 million illnesses, 18 million medical visits, 470,000 hospitalizations, and 28,000 deaths. Hence, the increasing incidence of influenza is propelling the growth of the antiviral market.

Which Segment Classifications Shape The Antivirals Market?

The antivirals market covered in this report is segmented –

1) By Type: Branded, Generic

2) By Drug Class: DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Other Drug classes

3) By Application: HIV, Hepatitis, Herpes, Influenza, Other Applications

Subsegments:

1) By Branded: Antivirals For HIV Or AIDS, Antivirals For Hepatitis, Antivirals For Influenza, Antivirals For Herpes Simplex Virus (HSV)

2) By Generic: Generic HIV Or AIDS Antivirals, Generic Hepatitis Antivirals, Generic Influenza Antivirals, Generic Herpes Simplex Virus (HSV) Antivirals

How Are Trends Impacting The Antivirals Market?

Leading companies in the antiviral market are prioritizing the development of innovative treatments, such as oral antiviral therapies, to enhance patient adherence, improve accessibility, reduce healthcare expenditures, and offer more convenient and effective options for managing viral infections. Oral antiviral treatment refers to medicines taken by mouth to combat viral infections. These therapies function by inhibiting viruses from replicating or spreading within the body, thereby helping to diminish the severity and duration of the infection. For example, in May 2023, Pfizer, a US-based pharmaceutical company, announced that Paxlovid received approval from the Food and Drug Administration, a US-based government agency, making it the first oral antiviral treatment for COVID-19 in adults. This approval is particularly significant as it introduces a new therapeutic choice for managing COVID-19, especially as the pandemic evolves into an endemic phase. Paxlovid is specifically indicated for adults with mild-to-moderate COVID-19 who are at high risk of progressing to severe disease, including hospitalization or death.

Major companies operating in the antiviral market are focusing on creating advanced therapeutic solutions, including various antiviral treatments, to improve patient outcomes and decrease viral transmission. Antiviral treatments are crucial for controlling viral infections and preventing complications in affected individuals. For instance, in August 2024, Red Queen’s Technology, a US-based pharmaceutical company, launched versatile antivirals. Apple Tree Partners has invested $55 million in Red Queen Therapeutics, a biotech firm dedicated to developing broad-spectrum antiviral treatments. The company targets infectious pathogens such as COVID-19 and influenza, having already advanced a COVID antiviral through Phase 1 testing and secured U.S. government funding for a pan-influenza drug. Co-founded by Harvard professor Loren Walensky, Red Queen employs stapled lipopeptides to inhibit viral fusion and block viral entry into cells.

Which Companies Are Expanding Their Footprint In The Antivirals Market?

Major companies operating in the antivirals market are AbbVie Inc., Bristol-Myers-Squibb Co., Chemical Industrial & Pharmaceutical Laboratories Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson & Johnson Services Ltd., Merck & Co. Inc., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Abbott Laboratories, Schering-Plough Corporation, Pfizer Inc., Sanofi-Synthélabo Ltd., Inovio Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., AVI Biopharma International Ltd., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Biogen Inc., Genentech USA Inc., Vertex Pharmaceuticals Inc.

Read the full antivirals market report here:

https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report

Which Geographic Regions Are Influencing Demand In The Antivirals Market?

North America was the largest region in the anti-viral drug therapy market in 2025. The Middle East is expected to be the fastest-growing region in the antivirals market during the forecast period. The regions covered in the antivirals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Antivirals Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2437&type=smp

Browse Through More Reports Similar to the Global Antivirals Market 2026, By The Business Research Company

Antivirals Market Report 2026

https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report

Antiviral Combination Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/antiviral-combination-therapy-global-market-report

Anti Infective Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the antivirals market from 2026–2035 with trusted insights from The Business Research Company

What is the estimated market size of the Antivirals Market by the end of 2030?

The antivirals market size has exhibited robust growth in recent years. It is forecast to increase from $114.4 billion in 2025 to $122.08 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.7%. Historically, this growth can be attributed to factors such as global viral outbreaks, the burden of hiv and hepatitis, government antiviral stockpiling, the availability of generics, and the expansion of infectious disease programs.

The antivirals market is anticipated to experience robust expansion over the coming years. This market is projected to reach a size of $163.33 billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.5%. The expansion during this projected timeframe can be attributed to factors such as emerging viral threats, increased investment in antiviral research and development, greater integration of vaccination and treatment, global health initiatives, and a growing demand for rapid-response therapeutics. Noteworthy trends identified for the upcoming period include an escalating demand for broad-spectrum antivirals, a heightened focus on pandemic preparedness, the wider availability of generic antiviral drugs, increased application in chronic viral infections, and the creation of antivirals with novel mechanisms.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2437&type=smp

What Drivers Are Shaping Future Opportunities In The Antivirals Market?

The growing occurrence of influenza is expected to drive the expansion of the antiviral market in the future. Influenza, commonly known as the flu, represents a highly transmissible viral respiratory illness initiated by influenza viruses, impacting the nasal passages, throat, and lungs. The increased frequency of influenza is largely attributed to cooler temperatures and indoor gatherings, conditions that enable the virus to persist longer and ease its transmission between individuals in close proximity. Antivirals serve as a treatment for influenza, formulated to hinder the proliferation and dispersion of influenza viruses inside the body. For instance, in November 2024, data from the Centers for Disease Control and Prevention, a national public health agency in the US, indicated that the 2023 to 2024 influenza season was linked to approximately 40 million illnesses, 18 million medical visits, 470,000 hospitalizations, and 28,000 deaths. Consequently, the rising incidence of influenza is propelling the growth of the antiviral market.

Which Segment Groups Are Influencing The Antivirals Market?

The antivirals market covered in this report is segmented –

1) By Type: Branded, Generic

2) By Drug Class: DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Other Drug classes

3) By Application: HIV, Hepatitis, Herpes, Influenza, Other Applications

Subsegments:

1) By Branded: Antivirals For HIV Or AIDS, Antivirals For Hepatitis, Antivirals For Influenza, Antivirals For Herpes Simplex Virus (HSV)

2) By Generic: Generic HIV Or AIDS Antivirals, Generic Hepatitis Antivirals, Generic Influenza Antivirals, Generic Herpes Simplex Virus (HSV) Antivirals

What Trends Are Driving The Growth Trajectory Of The Antivirals Market?

Leading pharmaceutical companies in the antiviral market are prioritizing the creation of novel therapies, notably oral antiviral treatments, to boost patient adherence, broaden access, lower medical expenses, and offer more convenient and potent solutions for viral disease management. Oral antiviral treatments are medicines administered orally for viral infections, functioning by impeding viral multiplication or dissemination within the body, thereby diminishing the infection’s intensity and duration. As an illustration, in May 2023, the US-based pharmaceutical firm Pfizer received approval from the Food and Drug Administration, a US-based government agency, for Paxlovid, making it the initial oral antiviral treatment for COVID-19 in adults. This landmark approval is crucial as it introduces a fresh treatment pathway for COVID-19, particularly as the pandemic evolves into an endemic state. Paxlovid is prescribed for adults experiencing mild-to-moderate COVID-19 who face a high probability of developing severe illness, including the need for hospitalization or a fatal outcome.

Key players in the antiviral market are concentrating on producing sophisticated therapeutic options, including antiviral treatments, to improve patient results and curb viral spread. Antiviral treatments play a vital role in managing viral infections and averting complications in infected individuals. For example, in August 2024, the US-based pharmaceutical company Red Queen’s Technology introduced a range of versatile antivirals. Apple Tree Partners invested $55 million into Red Queen Therapeutics, a biotechnology company focused on developing broad-spectrum antiviral treatments. This company aims to combat infectious agents like COVID-19 and influenza, having successfully advanced a COVID antiviral to Phase 1 trials and secured U.S. government funding for a universal influenza medication. Red Queen, co-founded by Harvard professor Loren Walensky, utilizes stapled lipopeptides to obstruct viral fusion and prevent viruses from entering cells.

Who Are The Core Companies Influencing Trends In The Antivirals Market?

Major companies operating in the antivirals market are AbbVie Inc., Bristol-Myers-Squibb Co., Chemical Industrial & Pharmaceutical Laboratories Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson & Johnson Services Ltd., Merck & Co. Inc., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Abbott Laboratories, Schering-Plough Corporation, Pfizer Inc., Sanofi-Synthélabo Ltd., Inovio Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., AVI Biopharma International Ltd., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Biogen Inc., Genentech USA Inc., Vertex Pharmaceuticals Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report

Which Regions Are Projected To Dominate The Antivirals Market In The Coming Years?

North America was the largest region in the anti-viral drug therapy market in 2025. The Middle East is expected to be the fastest-growing region in the antivirals market during the forecast period. The regions covered in the antivirals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Antivirals Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2437&type=smp

Browse Through More Reports Similar to the Global Antivirals Market 2026, By The Business Research Company

Antivirals Market Report 2026

https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report

Antiviral Combination Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/antiviral-combination-therapy-global-market-report

Anti Infective Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model